Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 15/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24838012 | 1.00 | ACACB (0.43) | ACACBKDM4ECYP2C19ALDH1A1LMNA | |
| SCHEMBL25467850 | 1.00 | ACACB (0.43) | ACACBKDM4ECYP2C19ALDH1A1LMNA | |
| SCHEMBL25475903 | 0.89 | ACACB (0.45) | ACACBKDM4ECYP2C19SLC6A9 | |
| SCHEMBL25604691 | 0.89 | ACACB (0.45) | ACACBKDM4ECYP2C19SLC6A9 | |
| SCHEMBL25475906 | 0.89 | ACACB (0.45) | ACACBKDM4ECYP2C19SLC6A9 | |
| SCHEMBL25475904 | 0.88 | ACACB (0.44) | ACACBKDM4ECYP2C19ALDH1A1LMNA | |
| SCHEMBL25600337 | 0.87 | ACACB (0.35) | ACACBKDM4ECYP2C19ALDH1A1LMNA | |
| SCHEMBL25600335 | 0.87 | ACACB (0.35) | ACACBKDM4ECYP2C19ALDH1A1LMNA | |
| SCHEMBL27051281 | 0.86 | ACACB (0.41) | ACACBACHE | |
| SCHEMBL26792093 | 0.86 | ACACB (0.41) | ACACBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| WO-2023278402-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | ACACB 1435/4885KDM4E 223/4885CYP2C19 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.